Woodline Partners LP Inhibrx, Inc. Transaction History

Woodline Partners LP

  • $9.97 Billion
  • Q2 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024
BUY
$14.5 - $38.0 $11.5 Million - $30.2 Million
793,661 Added 52.05%
2,318,576 $88.1 Million
Q2 2023

Aug 14, 2023
BUY
$16.96 - $27.82 $20.5 Million - $33.7 Million
1,210,720 Added 385.34%
1,524,915 $39.6 Million
Q1 2023

May 15, 2023
BUY
$18.45 - $27.14 $5.8 Million - $8.53 Million
314,195 New
314,195 $5.93 Million
Q3 2022

Nov 14, 2022
BUY
$11.58 - $24.73 $1.19 Million - $2.55 Million
103,097 New
103,097 $1.85 Million

Others Institutions Holding INBX

# of Institutions
2
Shares Held
25.3K
Call Options Held
0
Put Options Held
0
View Full List

About Inhibrx, Inc.

INBX Quotes by TradingView
  • Ticker INBX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,057,700
  • Market Cap $617M
  • Description
  • Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...
More about INBX
Track This Portfolio

Track Woodline Partners LP Portfolio

Follow Woodline Partners LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Woodline Partners LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email